A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Advanced Solid Malignancies · Non-small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC) · Pancreatic Ductal Adenocarcinoma (PDAC)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 252 (planned)
- Started
- Nov 25, 2025
- Main results expected
- Oct 13, 2028
- Fully finished
- Oct 13, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AEs)
Measured over: Up to 3 years
Number of participants with serious adverse events (SAEs)
Measured over: Up to 3 years
Number of participants with AEs meeting protocol-defined dose limiting toxicity (DLT) criteria
Measured over: Up to 3 years
Number of participants with AEs leading to discontinuation
Measured over: Up to 3 years
Number of deaths
Measured over: Up to 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07223047 · record last updated 2026-05-28 · checked 2026-11-09 15:47 UTC